MIRM News and Press, Mirum Pharmaceuticals Inc. From 12/18/23

2023-12-18 11:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-18 09:29:13 ET More on Mirum Pharmaceuticals Mirum Pharmaceuticals, Inc. (MIRM) Q3 2023 Earnings Call Transcript Mirum Pharmaceuticals: An Attractive Stock To Watch For Its Liver Disease Franchise JP Morgan bullish on six Big Biotechs, rates nine others neutr...

- Study did not meet primary or secondary endpoints. - LIVMARLI was generally well-tolerated, with no new safety findings. Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced top-line results of the Phase 2 EMBARK study evaluating LIVMARLI® (maralixibat) oral solution ver...

Dallas, Texas--(Newsfile Corp. - November 30, 2023) - Stonegate Healthcare Partners is pleased to announce the publication of its latest report, titled "Transformative Therapies for Pruritus Management." This comprehensive report delves into the critical issue of pruritus, or chronic itch, and it...

2023-11-25 16:32:53 ET More on BioCryst Pharmaceuticals, Crinetics Pharmaceuticals, etc. Mirum Pharmaceuticals, Inc. (MIRM) Q3 2023 Earnings Call Transcript BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2023 Earnings Call Transcript Immunocore: First Half Of 2024 IMC-F106...

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it is scheduled to present at the 6 th annual Evercore ISI H...

2023-11-13 14:38:40 ET More on Mirum Mirum Pharmaceuticals, Inc. (MIRM) Q3 2023 Earnings Call Transcript Mirum Pharmaceuticals: An Attractive Stock To Watch For Its Liver Disease Franchise Mirum Pharmaceuticals Q3 2023 Earnings Preview Cantor starts Mirum at ...

- Late-breaking poster presentation features LIVMARLI ® data showing long-term maintenance of response in patients with PFIC - Four poster presentations highlight LIVMARLI PFIC data as well as a poster with proof-of-concept trial data from volixibat study in intrahepatic cholestasis ...

2023-11-05 01:51:25 ET Mirum Pharmaceuticals, Inc. (MIRM) Q3 2023 Earnings Conference Call November 02, 2023, 16:30 ET Company Participants Andrew McKibben - VP, IR and Finance Christopher Peetz - President, CEO & Director Peter Radovich - COO Pamela Vig ...

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it is scheduled to participate in a fireside chat at the 2023 UB...